Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice
Morovat, A.; Weerasinghe, G.; Nesbitt, V.; Hofer, M.; Agnew, T.; Quaghebeur, G.; Sergeant, K.; Fratter, C.; Guha, N.; Mirzazadeh, M.; Poulton, J. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. J. Clin. Med. 2017, 6, 80. https://doi.org/10.3390/jcm6080080
Morovat A, Weerasinghe G, Nesbitt V, Hofer M, Agnew T, Quaghebeur G, Sergeant K, Fratter C, Guha N, Mirzazadeh M, Poulton J. Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice. Journal of Clinical Medicine. 2017; 6(8):80. https://doi.org/10.3390/jcm6080080
Chicago/Turabian StyleMorovat, Alireza, Gayani Weerasinghe, Victoria Nesbitt, Monika Hofer, Thomas Agnew, Geralrine Quaghebeur, Kate Sergeant, Carl Fratter, Nishan Guha, Mehdi Mirzazadeh, and Joanna Poulton. 2017. "Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical Practice" Journal of Clinical Medicine 6, no. 8: 80. https://doi.org/10.3390/jcm6080080